Do common risk variants near IRS1, CDKN2A/B, and SLC30A8 raise type 2 diabetes risk via impaired insulin signaling and beta‑cell dysfunction?

The genetic architecture of type 2 diabetes (T2D) is highly polygenic, involving distinct pathways that impair peripheral insulin action, beta-cell mass, and secretory dynamics. The common risk variants near IRS1 (rs2943641), CDKN2A/B (rs10811661), and SLC30A8 (rs13266634) represent crucial genetic nodes that influence these pathways.

Clinical and physiological evidence

• CDKN2A/B (rs10811661): This variant displays a pronounced physiological impact, with each risk allele increasing T2D odds by approximately 20% to 30%. It presents clinically as impaired glucose-stimulated insulin secretion, a reduced insulinogenic index, and decreased HOMA-beta, while peripheral insulin sensitivity remains unaffected.
• IRS1 (rs2943641): Carriers of this risk variant (particularly the CC genotype) demonstrate a per-allele odds ratio for T2D of 1.10 to 1.20, presenting clinically with elevated fasting insulin and elevated HOMA-IR scores.
• SLC30A8 (rs13266634): The C-allele conveys a 1.1 to 1.3 odds ratio for T2D, characterized by a reduced early-phase insulin secretory response to glucose and an elevated proinsulin-to-insulin ratio. This risk is further modulated by systemic zinc status; individuals with the high-risk CC genotype and low serum zinc exhibit the highest metabolic vulnerability.

Molecular and mechanistic pathways

• Insulin signaling decay (IRS1): The rs2943641 variant alters the downstream insulin-PI3K-Akt cascade. It shifts IRS1 phosphorylation toward inhibitory serine phosphorylation, reducing insulin-stimulated tyrosine phosphorylation and downstream GLUT4 translocation in metabolic tissues.
• Beta-cell proliferative decline (CDKN2A/B): The rs10811661 locus sits within islet enhancers and upregulates the expression of cell-cycle inhibitors p16INK4A and p15INK4B. This enforces cell-cycle arrest and senescence, limiting the regenerative reserve and adaptive expansion of beta-cells under metabolic stress.
• Secretory vesicle and maturation defects (SLC30A8): The rs13266634 (R325W) variant alters the cytosolic domain of the ZnT8 transporter, compromising zinc transport into insulin secretory granules. This limits insulin-zinc hexamer crystallization and proinsulin-to-insulin processing, though targeted zinc supplementation has been shown to rescue acute insulin secretion in risk-allele carriers.

Bottom line

• Bottom line: The risk variants near IRS1, CDKN2A/B, and SLC30A8 robustly elevate type 2 diabetes susceptibility through three distinct, synergistic pathophysiological mechanisms: IRS1 rs2943641 blunts peripheral insulin sensitivity, CDKN2A/B rs10811661 restricts pancreatic beta-cell mass and regeneration, and SLC30A8 rs13266634 impairs zinc-dependent insulin crystallization and acute secretion.